All News

Ocrelizumab Holds Benefit for Relapsing MS Patients With Prior Suboptimal DMT Response

September 22, 2020

Treatment with ocrelizumab can improve freedom from individual events in patients with relapsing-remitting multiple sclerosis regardless of suboptimal DMT response in the past.

The Importance of Patient-Centered Care in Parkinson Disease

September 22, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS

September 22, 2020

The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

September 21, 2020

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

September 21, 2020

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

World Alzheimer’s Day 2020: The Latest News and Commentary on the Treatment of Alzheimer Disease

September 21, 2020

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.

Optimal Management of OFF Episodes in Parkinson's Disease

September 21, 2020

Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy.

The Changing Treatment Landscape for Acute Migraine

September 21, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

Jonathan Graff-Radford, MD: Importance of World Alzheimer’s Day

September 21, 2020

The neurologist at Mayo Clinic shared his thoughts on the need to raise awareness of Alzheimer disease on World Alzheimer’s Day.

Ganaxolone Meets Primary End Point in CDKL5 Deficiency Disorder Study

September 20, 2020

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.